Search
Madrid Declaration: joint call for action on training requirements
The Madrid Declaration on enhanced training requirements for hematologists in the Professional Qualifications Directive enjoyed broad support from national society representatives at the EHA22 National Societies Dinner in Madrid.
Read moreLymphomas from A to Z
Nineteen countries from 3 continents were represented during the EHA-SWG Scientific Meeting on Rare Lymphomas on March 10-12, 2017 in Barcelona, Spain.
Read moreEuroBloodNet aims for better care for patients with rare blood disorders
ERNs is an initiative of the European Commission and consist of networks of healthcare providers and centers of excellence in Europe aimed at improving quality, safety, and access to highly specialised healthcare.
Read moreImpact of new technologies on diagnosis and treatment of anemias highlighted in scientific meeting
Hematologists from 18 countries and 4 continents learned more about the new techniques for diagnosis and treatment of anemias during the EHA-SWG Scientific Meeting on Anemias on February 2-4, 2017 in Barcelona, Spain.
Read moreEuropean Reference Networks, a unique opportunity to take collaboration and patient care in hematology to the next level, was a core topic at EHA 2016
On Saturday 11 June, a session in the Patient Advocacy Track focused on the emerging European Reference Networks (ERNs).
Read moreImproved survival for adult Acute Lymphoblastic Leukemia (ALL) patients
Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.
Read moreDaratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study
Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.
Read moreThe root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.
Read morePRESS RELEASE: The future of research in hematology is here
“For the first time, hematologists in Europe came together to develop a roadmap to guide hematology research in Europe” says Professor Andreas Engert, chair of the EHA Research Roadmap Task Force, “Hematology in Europe has achieved a lot, but the discipline must focus and…
Read moreA European Reference Network for Rare Hematological Diseases
You may have heard of European Reference Networks (ERNs). But most likely you have not. ERNs are networks of specialized hospital departments and research centers to treat rare or low-prevalent complex diseases.
Read more